Transcriptional control of enterohepatic lipid regulatory targets in response to early cholesterol and phytosterol exposure in apoE−/− mice

Anthony Juritsch1, Yi‑Ting Tsai1, Mulchand S. Patel2 and Todd C. Rideout1*

Abstract

Objective: An excessive rise in blood lipids during pregnancy may promote metabolic dysfunction in adult progeny. We characterized how maternal phytosterol (PS) supplementation affected serum lipids and the expression of lipid‑regulatory genes in the intestine and liver of newly‑weaned apo‑E deficient offspring from dams fed a chow diet supplemented with cholesterol (0.15%, CH) or cholesterol and PS (2%) (CH/PS) throughout pregnancy and lactation.

Results: Serum lipid concentrations and lipoprotein particle numbers were exacerbated in offspring from cholesterol‑supplemented mothers but normalized to chow‑fed levels in pups exposed to PS through the maternal diet during gestation and lactation. Compared with the CH pups, pups from PS‑supplemented mothers demonstrated higher (p < 0.05) expression of the primary intestinal cholesterol transport protein (Niemann‑Pick C1‑like 1) and the rate‑limiting enzyme in hepatic cholesterol synthesis (HMG‑CoAr), suggestive of a compensatory response to restore cholesterol balance. Furthermore, pups from PS‑supplemented mothers exhibited a coordinated downregulation (p < 0.05) of several genes regulating fatty acid synthesis including PGC1β, SREBP1c, FAS, and ACC compared with the CH group. These results suggest that maternal PS supplementation during hypercholesterolemic pregnancies protects against aberrant lipid responses in newly‑weaned offspring and results in differential regulation of cholesterol and lipid regulatory targets within the enterohepatic loop.

Keywords: Maternal hypercholesterolemia, Offspring, Phytosterols, Liver, Intestine, mRNA

Introduction

Hypercholesterolemia is a considerable public health issue in the United States affecting roughly 30% of the population [1]. Transient elevations in maternal blood lipids during pregnancy are essential for embryogenesis, early organ development, and whole‑body fetal growth [2–5]. However, a growing body of literature suggests that excessive maternal hyperlipidemia during pregnancy, termed maternal supraphysiological hypercholesterolemia (MSPH) [6, 7], can adversely program fetal lipid metabolism predisposing offspring to increased cardiovascular disease (CVD) risk as adults by altering hepatic cholesterol metabolism [8, 9] and accelerating the development of arterial fatty streaks [10] and advanced arterial lesions [11]. Napoli et al. [10] reported that aborted fetuses from hypercholesterolemic mothers had significantly more and larger lesions compared with those from mothers with a normal cholesterol range [10]. A follow up autoptic study including 156 children (1–14 years old) suggested that although fetal fatty streaks may regress after birth, arterial lesions develop ‘strikingly’ faster in children whose mothers were hypercholesterolemic during pregnancy versus normcholesterolemic mothers [11].

As the use of statins in expectant mothers and women trying to conceive is contraindicated due to potential...
teratogenic effects [12], we have conducted studies to examine if phytosterols (PS), plant-based cholesterol-lowering compounds, have utility in the prevention and management MSPH [13, 14]. Results from these studies suggest that newly-weaned offspring from PS-supplemented mothers during gestation and lactation are largely protected against an early dyslipidemic phenotype compared with offspring from hypercholesterolemic mothers. However, the potential molecular mechanisms associated with these lipid responses have yet to be examined. Thus, the primary objective of this study was to characterize alterations in lipid regulatory gene expression within the enterohepatic loop in newly-weaned apoE deficient offspring exposed to PS through the maternal diet during gestation and lactation. We have used the apoE deficient mouse as this model demonstrates a genetic predisposition to hypercholesterolemia which is further exacerbated upon consumption of a high cholesterol diet [15], responds to the cholesterol-lowering actions of phytosterols (unlike wildtype C57BL/6J mice) [16–19], and has been utilized in previous maternal programming studies to examine excessive early cholesterol exposure [20, 21].

**Main text**

**Methods**

The experimental design has been described previously [14]. In short, twenty-four mature (3-month old) female mice homozygous for disruption of the apoE gene (apoE<sup>−/−</sup>, strain B6.129P2-Apoetm1Unc<sup>/</sup>J) were purchased from Jackson laboratory. The mice were randomly assigned (n = 8/group) to 1 of 2 commercial nonpurified diets (Teklad 2019 Harlan Laboratories (% energy from protein, 21.4; fat, 19.9; and carbohydrate, 58.7): (i) cholesterol supplemented chow (CH, TD.140285), and (ii) cholesterol (0.15%, w/w) and PS (2%, w/w) supplemented chow (CH/PS, TD.140286; PS sourced from Forbs Medi-Tech Corp, Kearny, N J). An additional control group of chow-fed animals were included (n = 8) to provide reference values for the normal blood lipid and lipoprotein measurements in newly-weaned apoE deficient offspring but were not used for subsequent gene expression studies. Females were mated for 1 week (1 male per 2 females) with male apoE<sup>−/−</sup> KO breeders (maintained on a chow diet) and litters were culled to n = 6 pups per dam to minimize variability in postnatal pup development influenced by litter size. Throughout the suckling period the dams remained on their respective diets. At weaning (d21), the dams and pups were anesthetized with isoflurane for blood and tissue collection.

Fasting (15 h) blood was collected by cardiac puncture and intestinal and liver tissue were excised and stored at −80 °C for further processing. Serum cholesterol panel (total-C, HDL-C, and direct LDL-C) and triglyceride (TG) were analyzed by automated enzymatic kits (Sekisui Diagnostics, Lexington, MA, USA) on an ABX Pentra 400 autoanalyzer (Horiba Instruments Inc, Irvine CA, USA) using appropriate calibrators and controls as specified by the manufacturer. Lipoprotein particle number was analysed by nuclear magnetic resonance spectroscopy (LabCorp) [22]. Serum PCSK9 concentration was measured in serum by ELISA according to the manufacturer instructions (R&D Systems, MPCR90).

RNA extraction and real-time RT-PCR were conducted according to previously published procedures [13]. Gene expression was analyzed using the 2(δ-δCT) method [36]. Sequences of gene primers were based on previously published reports for β-actin [23], peroxisome proliferator-activated receptor α (PPARα) [24], carnitine palmitoyltransferase Iα (CPT1α) [25], peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC1β) [26], sterol regulatory element binding protein 1c (SREBP1c) [27], acetyl-coA carboxylase 1 (ACC1) [28], fatty acid synthase (FAS) [29], 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA) [30], SREBP cleavage activating protein (SCAP) [30], low-density lipoprotein receptor (LDLr) [31], proprotein convertase subtilisin/kexin type 9 (PCSK9) [32], sterol regulatory element-binding protein 2 (SREBP2) [31], liver X receptor (LXR) [27], ATP binding cassette subfamily A member 1 (ABCA1) [31], ATP binding cassette subfamily G member 1 (ABCG1) [31], ATP binding cassette subfamily G member 5 (ABCG5) [31], ATP binding cassette subfamily G member 8 (ABCG8) [31], niemann-pick C1-like 1 (NPC1L1) [33], organic solute transporter α and β (Ostα/β) [34], farnesoid X-activated receptor (FXR) [31], microsomal triglyceride transfer protein (MTP) [31], fatty acid binding protein 2 (FABP2) [35], cluster of differentiation 36 (CD36) [36], and low-density lipoprotein receptor (LDLR) [37].

**Statistical analyses**

Litters from each dam were counted as a single observation. Blood lipids and lipoproteins concentrations in the main treatment groups (CH and CH/PS) were compared alongside normal chow-fed offspring using a general linear model ANOVA with a Bonferroni post hoc test [38]. Gene expression patterns were compared between the CH and CH/PS groups only using a one-way ANOVA. Data were analyzed with SPSS 16 for Mac (SPSS Inc, Chicago, IL). Data are presented as mean ± SEM. Differences were considered significant at p ≤ 0.05. One dam in the CH/PS group was terminated early, therefore the final number of animals per group was n = 8 chow, n = 8 CH, and n = 7 CH/PS.
Results

At gestation week 2, cholesterol-fed mothers (CH) demonstrated higher (p < 0.05) serum total cholesterol (+70%) and triglyceride (+28%) concentrations compared with chow mothers, but this response was normalized in the CH/PS mice (Table 1). Maternal cholesterol feeding during gestation and lactation resulted in dyslipidemic newly-weaned pups with higher (p < 0.05) serum total-cholesterol, LDL-C, and TG compared to chow pups (Table 1). However, maternal PS supplementation protected against this dyslipidemic response with offspring from PS-supplemented mothers demonstrating lower (p < 0.05) serum lipids (total-C, LDL-C and TG) compared with the CH groups. No change (p > 0.05) was observed in HDL-C concentrations between the groups. Additionally, offspring from cholesterol-fed mothers (CH) had higher total number of serum LDL, HDL, and VLDL particles compared to the chow group but this was normalized to chow-fed levels upon maternal PS supplementation.

Compared with CH offspring, offspring from PS-supplemented mothers demonstrated higher (p < 0.05) intestinal NPC1L1 (+1.6-fold of CH, Fig. 1a) expression and lower (p < 0.05) expression of the alpha sub-unit (OSTa) of the heterodimeric ileal basolateral bile acid transport protein OSTa/OSTb (0.6-fold of CH, Fig. 1a). No changes (p > 0.05) in lipid regulatory targets were observed between the two groups (Fig. 1b).

New-weaned pups from PS-supplemented mothers demonstrated higher (p < 0.05) hepatic mRNA expression of HMG-CoAr (+5.4-fold of CH), SCAP (+1.7-fold of CH), and PCSK9 (+1.4-fold of CH) compared with the CH group (Fig. 2a). However, increased hepatic PCSK9 transcription did not reflect in any change (p > 0.05) in serum PCSK9 concentration between the CH and CH/PS groups (10.8 ± 2.2 vs. 12.6 ± 1.5 μg/mL, respectively). Although no difference was observed between the CH and CH/PS groups in the expression of hepatic fat oxidative regulators (CPT1α or PPARα), pups from PS-supplemented mothers demonstrated a reduction (p < 0.05) in several genes that regulate fatty acid synthesis including PGC1β (0.5-fold of CH), SREBP1c (0.43-fold of CH), FAS (0.55-fold of CH), and ACC (0.49-fold of CH) (Fig. 2b).

Discussion

Serum lipids and lipoprotein concentrations were exacerbated in offspring from cholesterol-supplemented mothers but were normalized to chow-fed levels in pups exposed to PS through the maternal diet during gestation and lactation. Gene expression results indicate that due to a likely interference with in utero and/or postnatal cholesterol transfer, offspring from PS supplemented mothers had enhanced intestinal cholesterol absorption and hepatic cholesterol synthesis as reflected by higher NPC1L1 and HMG-CoAr expression, respectively. Results further suggest that early exposure to PS resulted in a coordinated reduction in hepatic lipogenic gene expression which may underlie the TG-lowering response observed in these animals.

The effects of maternal PS supplementation on lipid metabolism in newly-weaned offspring is likely mediated through multiple contributing mechanisms including the limitation of excessive cholesterol transfer during gestation, the alteration of lipid milk composition during the suckling period, and/or direct effects of PS on lipid-regulatory gene expression patterns within offspring. The expression of a variety of lipid transport proteins in placental trophoblasts and endothelial cells regulates the transfer of lipids and cholesterol from the maternal to the fetal circulation [39, 40]. A lowering of total body cholesterol balance in PS-supplemented mothers, as evidenced by reduced gestational serum cholesterol and TG, would likely limit cholesterol transfer between the mother and developing fetus. However, as far as we are aware, there are no studies examining placental lipid transport in response to PS. It is equally likely that interruption of maternal lipid transfer during lactation could have contributed to the observed lipid changes in offspring through altered milk composition of cholesterol and/or TGs. However, in a previous human study, Mellies et al. [41] detected no change in cholesterol concentration in breast milk following maternal PS supplementation in the lactation period (30 days) despite a reduction in maternal plasma cholesterol levels [41]. Whether maternal PS supplementation inhibited cholesterol transfer to offspring

Table 1 Serum lipids in dams (gestation week 2) and newly weaned offspring (postnatal day 21) from mothers fed a chow diet, the chow diet supplemented with cholesterol (CH), or cholesterol and phytosterol (CH/PS) during gestation and lactation

| Endpoint                     | Chow     | CH      | CH/PS   |
|------------------------------|----------|---------|---------|
| Maternal lipids (mmol/L), gestation week 2 |          |         |         |
| Total-C                      | 3.73 ± 0.51<sup>a</sup> | 6.36 ± 1.23<sup>b</sup> | 4.23 ± 0.34<sup>a</sup> |
| Triglycerides                | 0.61 ± 0.02<sup>a</sup> | 0.78 ± 0.09<sup>b</sup> | 0.60 ± 0.02<sup>a</sup> |
| Offspring lipids (mmol/L), postnatal day 21 |          |         |         |
| Total-C                      | 10.9 ± 0.4<sup>a</sup> | 12.5 ± 0.5<sup>b</sup> | 9.4 ± 0.3<sup>c</sup> |
| LDL-C                        | 2.6 ± 0.1<sup>a</sup> | 3.62 ± 0.1<sup>b</sup> | 1.88 ± 0.1<sup>c</sup> |
| HDL-C                        | 0.60 ± 0.0<sup>a</sup> | 0.67 ± 0.1<sup>a</sup> | 0.53 ± 0.0<sup>a</sup> |
| Triglycerides                | 1.13 ± 0.0<sup>a</sup> | 2.09 ± 0.4<sup>b</sup> | 1.22 ± 0.1<sup>a</sup> |
| Offspring lipoprotein particle number (μmol/L), postnatal day 21 |          |         |         |
| Total LDL Particles          | 378.1 ± 27.7<sup>a</sup> | 676.3 ± 114.0<sup>b</sup> | 442.5 ± 28.5<sup>a</sup> |
| Total HDL Particles          | 123.5 ± 0.5<sup>a</sup> | 163.6 ± 1.6<sup>b</sup> | 115.5 ± 0.5<sup>a</sup> |
| Total VLDL Particles         | 217.9 ± 9.9<sup>a</sup> | 2924 ± 92.9<sup>b</sup> | 201.3 ± 6.7<sup>a</sup> |

<sup>a,b,c</sup> Groups not sharing a superscript are significantly different (p < 0.05). Data are mean ± SE; n = 8 chow, n = 8 CH, n = 7 CH/PS
in utero or during lactation, gene expression data in both the intestine and liver support a compensatory increase in intestinal cholesterol uptake through the primary intestinal cholesterol transport protein NPC1L1 [42] and the rate-limiting enzyme in hepatic cholesterol, HMG-CoAr. This gene expression pattern may well reflect an effort to restore cholesterol lipid balance as cholesterol is critical for early development [43]. Although there are no other maternal PS supplementation studies with which to compare our gene expression data, previous PS supplementation studies in adult animals have reported variable expression of NPC1L1 [44–47] and a more consistent increase in HMG-CoAr expression [48, 49] and cholesterol synthesis [50–52].

We observed a coordinated reduction in the hepatic expression of a host of regulatory genes involved in de novo fatty acid synthesis including the rate-limiting enzymes ACC and FAS a reduction in the expression of PGC1β and SREBP1, critical molecular regulators that enhance hepatic fat synthesis [53]. In support of these observations, we recently reported a reduction in de novo lipogenesis and an associated down-regulation of hepatic FAS protein abundance in adult male Syrian golden hamsters fed a high fat diet supplemented with
PS [54]. It is tempting to speculate that the reduction in hepatic lipogenic genes may be related to the lower serum TG and VLDL particles observed in pups from PS-supplemented mothers. In support of a TG-lowering mechanism of hepatic origin, Schonewille et al. recently reported a reduction in hepatic VLDL secretion in male C57BL/6 J mice fed a high fat diet supplemented with 3.1% PS or stanol esters for 3 weeks [55].

In summary, maternal hypercholesterolemia during pregnancy resulted in an overt dyslipidemia in newly-weaned pups that was normalized through maternal PS supplementation throughout the pregnancy and lactation periods. Pups from PS-supplemented mothers demonstrated higher intestinal NPC1L1 and hepatic HMG-CoAr mRNA expression, suggestive of a compensatory response to restore cholesterol balance. The effects of maternal PS supplementation in normalizing blood TG concentration and VLDL particle numbers is likely associated with a coordinated down-regulation of hepatic lipogenic gene expression.

Fig. 2 Hepatic mRNA expression of cholesterol (a) and lipid regulatory targets (b) in newly-weaned apo-E deficient mice from mothers fed a cholesterol-enriched chow diet (CH) or the chow diet supplemented with cholesterol and phytosterol (CH/PS) during gestation and lactation. All genes were normalized to the CH group and expressed relative to β-actin. *denotes significance (p < 0.05). Data are mean ± SE; n = 8 CH, n = 7 CH/PS
Limitations
Although our data demonstrates hepatic transcriptional changes in lipid regulatory genes in newly-weaned offspring exposed to excessive cholesterol and the protective effects of maternal PS supplementation, it is unclear if these changes are the result of prenatal versus postnatal exposure and if the observed hepatic adaptations will persist into adult life.

Abbreviations
PS: phytosterols; CH: cholesterol supplemented chow; CH/PS: cholesterol supplemented chow with PS; PPARa: peroxisome proliferator-activated receptor α; CPT1c: carnitine palmitoyltransferase 1c; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-beta; SREBP1c: sterol regulatory element binding protein 1c; ACC1: acetyl-CoA carboxylase 1; FAS: fatty acid synthase; HMG-CoAr: 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; SCAP: SREBP cleavage activating protein; LDLr: low-density lipoprotein receptor; PCSK9: proprotein convertase subtilisin/kexin type 9; SREBP2: sterol regulatory element-binding protein 2; LXR: Liver X receptor; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ABCG5: ATP binding cassette subfamily G member 5; ABCG8: ATP binding cassette subfamily G member 8; NPC1L1: niemann-pick C1-like 1; Ostα/β: organic solute transporter α and β; FXR: farnesoid X-activated receptor; MTP: microsomal triglyceride transfer protein; FABP2: fatty acid binding protein 2; CD36: cluster of differentiation 36; LDLR: low-density lipoprotein receptor.

Authors’ contributions
AJ and YT conducted the animals experiments and the laboratory analysis, MP and TCR designed the study, interpreted the results, and wrote the manuscript. All authors have read and approved the final manuscript.

Author details
1 Departments of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14214, USA. 2 Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14214, USA.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval
The animals used in this experiment were cared for in accordance with the guidelines established by the Institutional Animal Care and Use Committee (IACUC) at the University at Buffalo. All procedures were reviewed and approved by the Animal Care Committee at the University at Buffalo (protocol # PTE16082 N).

Funding
This research was supported by a KO1 Grant (IKK1 AT007826-01A1) from the National Center for Complementary and Integrative Health (NCCIH) and a KO1 supplement from NCCIH and the Office of Dietary Supplements (3K01 AT007826-03S1) (to TCR).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 24 February 2017 Accepted: 23 October 2017 Published online: 30 October 2017

References
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
2. Roberg-Larsen H, Strand MF, Krauss S, Wilson SR. Metabolites in vertebrate Hedgehog signaling. Biochem Biophys Res Commun. 2014;446:669–74.
3. Phan BA, Toth PP. Dyslipidemia in women: etiology and management. Int J Womens Health. 2014;6:185–94.
4. Witztumer A, Mayer A, Novack V, Sheiner E, Glutuz H, Malhotra A, Novack L. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009;201(482):e481–8.
5. Huda SS, Sattar N, Freeman DJ. Lipoprotein metabolism and vascular complications in pregnancy. Clin Lipidol. 2009;4:91–102.
6. Witztumer A, Mayer A, Novack V, Sheiner E, Glutuz H, Malhotra A, Novack L. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009;201:482.e481–8.
7. Leiva A, de Medina CD, Salisso R, Saez T, San Martin S, Abazarz A, Farias M, Guzman-Gutierrez E, Pardo F, Sobrevia L. Maternal hypercholesterolemia in pregnancy associates with umbilical vein endothelial dysfunction role of endothelial nitric oxide synthase and arginase II. Arterioscler Thromb Vasc Biol. 2013;33:2444–53.
8. Marseille-Tremblay C, Ethier-Chasson M, Forest J, Giguere Y, Masse A, Mounier C, Lafond J. Impact of maternal circulating cholesterol and gestational diabetes mellitus on lipid metabolism in human term placenta. Mol Reprod Dev. 2008;75:1054–62.
9. Goikhnay N, Tamayo EH, Yin H, Hankins GD, Saade GR, Longo M. Maternal hypercholesterolemia leads to activation of endogenous cholesterol synthesis in the offspring. Am J Obstet Gynecol. 2008;199:273.e271–273, e271.
10. Napoli C, D’Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palmbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680–90.
11. Napoli C, Glass CK, Witztum JL, Deutsch R, D’Armiento FP, Palinski W. Influence of maternal hypercholesterolemia on progression of early atherosclerotic lesions in childhood: fate of early lesions in children (FELIC) study. Lancet. 1999;354:1284–41.
12. Eapen DJ, Vallani K, Reddy S, Sperling L. Management of familial hypercholesterolemia during pregnancy: case series and discussion. J Clin Lipidol. 2012;6:88–91.
13. Liu J, Iqbal A, Raslavska B, Browne RW, Patel MS, Rideout TC. Influence of maternal hypercholesterolemia and phytosterol intervention during gestation and lactation on dyslipidemia and hepatic lipid metabolism in offspring of Syrian golden hamsters. Mol Nutr Food Res. 2016;60:2151–60.
14. Rideout TC, Movsesian C, Tsai YT, Iqbal A, Raslavska B, Patel MS. Maternal phytosterol supplementation during pregnancy and lactation modulates lipid and lipoprotein response in offspring of apoE-deficient mice. J Nutr. 2015;145:1726–34.
15. Moghadasi MH, McManus BM, Nguyen LB, Shefer S, Nadji M, Godin DV, Green TJ, Hill J, Yang Y, Scudamore CH, Frohlich JJ. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apoE-related disorders in humans. FASEB J. 2001;15:2623–30.
16. Rideout TC, Harding SV, Mackay D, Abumweis SS, Jones PJ. High basal fractional cholesterol synthesis is associated with nonresponse of plasma LDL cholesterol to plant sterol therapy. Am J Clin Nutr. 2010;92:41–6.
17. Ploch T, Kruit JK, Bloks VW, Huijkman NC, Havinga R, Duchateau GS, Lin Y, Kuipers F. Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J Nutr. 2006;136:2135–40.
18. Calpe-Berdili L, Escola-Gil JC, Ribas V, Navarro-Sastre A, Garces-Garces J, Blanco-Vaca F. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis. 2005;181:75–85.

19. Weingartner O, Lutjohann D, Ji S, Weisshoff N, List F, Sudhop T, von Blomberg K, Gerke K, Konig J, Schafers HJ, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51:1533–61.

20. Alkemade FE, van Vliet P, Henneman P, van Dijk KW, Hierck BP, van Munsteren JC, Scheeerman JA, Goeman JJ, Havekes LM, Gittenberger-de Groot AC, et al. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol. 2010;176:542–8.

21. Goharkhay N, Sbrana E, Gamble PK, Tamayo EH, Betancourt A, Villarreal R, Hakins GD, Saade GR, Longo M. Characterization of a murine model of fetal programming of atherogenesis. Am J Obstet Gynecol. 2007;197(416ei):e11–5.

22. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:947–70.

23. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Bumpus NN, Johnson EF. 5-Aminoimidazole-4-carboxamide-ribonucleoside inhibits Cyp4a31, and other peroxisome proliferator-activated receptor alpha-responsive mouse genes is AKAR 5'-monophosphate-dependent and AMP-activated protein kinase-independent. J Pharmacol Exp Ther. 2011;339:886–95.

24. Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases expression of hepatic gene associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2004;289:F656–72.

25. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretto S, Loda M. The isopeptidase USP2A regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004;5:253–61.

26. Zhang G, Li Q, Wang L, Chen Y, Wang L, Zhang W. Interleukin-1beta response to a phytosterol-enriched diet. Atherosclerosis. 2005;181:75–85.

27. Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, Kathirvel E, French BL, Batta AK, Shefer S, Salen G. Effect of high plant sterol-enriched diet on hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis. 2012;224:401–10.

28. Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, Fan Y, Zhang Y, Zhu Y, Wang N, et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008;295:F662–71.

29. Wu M, Dong B, Cao A, Li H, Liu J. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis. 2012;224:401–10.

30. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Lipid Res. 2005;28:12710–20.

31. Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci USA. 2008;105:3891–6.

32. Sekar R, Chow BK. Secretin receptor-knockout mice are resistant to high-fat diet-induced obesity and exhibit impaired intestinal lipid absorption. FASEB J. 2014;28:3404–505.